Ben Doak

Head of Innovative Treatments at NHS England

Speaker

Ben Doak is the Head of Innovative Treatments at NHS England.

Ben’s primary role is to fulfil NHS England’s commissioning responsibility to ensure that services are in place so that patients can benefit from licensed ATMPs recommended by NICE (the National Institute of Health and Care Excellence) in the NHS in England.

Since commencing his current role in 2020, Ben has overseen the expansion of CAR-T services in the England as well supporting access to ATMPs such as Casgevy for transfusion-dependent beta-thalassaemia, Hemgenix for haemophilia B and Zolgensma for spinal muscular atrophy. He maintains an active interest in horizon scanning of ATMPs and other innovative treatments.